DUBLIN--(BUSINESS WIRE)--The "Sepsis Diagnostics Market by Technology, Product, Method, Test Type, Pathogen, End-User - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
The global sepsis diagnostics market is projected to reach USD 613.9 million by 2023 from USD 396.6 million in 2018, at a CAGR of 9.1%.
Rising incidence of sepsis, rising geriatric population, growing number of surgical procedures, high incidence of hospital-acquired infections, and commercialization and availability of a wide variety of approved sepsis diagnostic devices are the factors expected to drive the market during the study period. However, the lack of established reimbursement policies for sepsis and high cost of automated diagnostic devices are the major factors restraining the growth of this market.
On the basis of technology, the microbiology segment is expected to command the largest share of the global sepsis diagnostics market in 2018. The large share of this segment can be attributed to the growing use of blood culture techniques for the diagnosis of sepsis.
On the basis of products, the market is segmented into blood culture media, instruments, assays & reagents, and software. The blood culture media segment is expected to be the fastest-growing segment during the forecast period. The large share of this segment can be attributed to the fact that blood culture testing is used as the standard diagnostic method for the diagnosis and identification of sepsis across the globe.
Geographically, the sepsis diagnostics market is segmented into North America, Europe, Asia Pacific, and RoW. Asia Pacific is expected to register the highest growth rate during the forecast period due to the high prevalence of sepsis, increasing number of surgical procedures, growing number of clinical studies, and developing healthcare infrastructure in this region.
The major players of the sepsis diagnostics market are bioMrieux (France), T2 Biosystems (US), Luminex (US), Thermo Fisher Scientific (US), Bruker (US), Abbott (US), Roche (Switzerland), Danaher (US), Becton, Dickinson, and Company (US), EKF Diagnostics (UK), Immunexpress (Australia), Response Biomedical (Canada), Axis-Shield Diagnostics (UK), CytoSorbents (US), and Mitsubishi Chemical Europe (Germany).
Key Topics Covered
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Sepsis Diagnostics Market, by Technology
7 Sepsis Diagnostics Market, by Product
8 Sepsis Diagnostics Market, by Method
9 Sepsis Diagnostics Market, by Pathogen
10 Sepsis Diagnostics Market, by Test Type
11 Sepsis Diagnostics Market, by End User
12 Sepsis Diagnostics Market, by Region
13 Competitive Landscape
14 Company Profiles
- Axis-Shield Diagnostics
- Becton, Dickinson, and Company (BD)
- EKF Diagnostics
- Mitsubishi Chemical Europe
- Response Biomedical
- Roche Diagnostics (A Subsidiary of F. Hoffmann-LA Roche Ltd.)
- T2 Biosystems
- Thermo Fisher Scientific
For more information about this report visit https://www.researchandmarkets.com/research/wx9kz2/global_sepsis?w=4